Foghorn Therapeutics Inc. announced that new clinical and pre-clinical data for its BRG1/BRM inhibitor FHD-286, pre-clinical data for its selective EP300 program, and pre-clinical data for the BRD9 degrader FHD-609, will be presented at the AACR-NCI-EORTC International Conference. The conference will be held October 11-15, 2023, in Boston, Massachusetts. Foghorn will highlight data from its FHD-286 program demonstrating its potential as a broad-based hematologic and solid tumor differentiation agent, including clinical data in acute myeloid leukemia (AML), metastatic uveal melanoma (mUM), and pre-clinical data in non-small cell lung cancer (NSCLC) and prostate cancer.

FHD-286 is a potent, selective inhibitor of the BRG1 and BRM sub units of the BAF chromatin remodeling complex where dependency on BRM/BRG1 is well-established pre-clinically in multiple tumor types, including UM, AML/myelodysplastic syndrome (MDS), NSCLC, and other solid tumor types. Also at AACR-NCI- EORTC, the Company will present data from its selective EP300 program, including in vitro selective degradation and antiprol proliferation in AR+ prostate and DLBCL cell lines. The EP300 program targets CBP mutant cancers and subsets of EP300 dependent malignancies, which include bladder, NSCLC, and various leukemias and lymphomas.

In addition, the Company will present results from next-generation-sequencing (NGS) analyses exploring the mechanism by which degradation of BRD9 may lead to proliferation defects in synovial sarcoma, as well as results from in vitro and in vivo studies demonstrating the anti-tumor efficacy of FHD-609, a BRD9 degrader, in a sub-type of AML.